Experimental Hematology

Elsevier BV

Journal websitePeer review: Peer review
Evaluation status available after sign-in

About the journal

Experimental Hematology is a journal published by Elsevier BV in United States. It is listed in MEDLINE according to the sources read. Declared publication charge: 3,000 USD. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
Elsevier BV
ISSN
1873-2399 · 0301-472X
Country
United States
Access
Not open access / not declared
Declared publication charge
3,000 USD
Declared peer-review model
peer_review

Index listings

  • MEDLINE · 1973-01-01
Indexing
MEDLINE
APC
3,000 USD
Declared review time (DOAJ)
—
Actual review time (measured)
85 days received→accepted — computed from PubMed (n=96)
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Works in OpenAlex

8294

Last recorded publication year

2026

Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

141

i10-index

2703

From OpenAlex open data (CC0).

Editorial & policy4
Observed digital preservation (Keepers registry)— snapshot 2026-10-05
CLOCKSSPortico
Norwegian register (HK-dir)— 2026
Level 1 — approved scholarly channel
Open references deposited at Crossref
28%
ORCID iDs in current deposits
24%
Deposits licence metadata at Crossref
✓
Identity & continuity3
Source type
journal
NLM unique ID (PubMed)
0402313
Classification(no data)

No data available to the platform for this group

No platform data for: Classification — absence is not a judgment about the journal.

Subject areas

  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Acute Myeloid Leukemia Research
  • Mesenchymal stem cell research
  • Mesenchymal stem cell research
  • Immune Cell Function and Interaction
  • Immune Cell Function and Interaction
Show all subjects (50)
  • T-cell and B-cell Immunology
  • T-cell and B-cell Immunology
  • Erythrocyte Function and Pathophysiology
  • Erythrocyte Function and Pathophysiology
  • Zebrafish Biomedical Research Applications
  • Zebrafish Biomedical Research Applications
  • Chronic Myeloid Leukemia Treatments
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Epigenetics and DNA Methylation
  • Epigenetics and DNA Methylation
  • Immune cells in cancer
  • Platelet Disorders and Treatments
  • Platelet Disorders and Treatments
  • Immune cells in cancer
  • Acute Lymphoblastic Leukemia research
  • Acute Lymphoblastic Leukemia research
  • Immunotherapy and Immune Responses
  • Immunotherapy and Immune Responses
  • Hemoglobinopathies and Related Disorders
  • Hemoglobinopathies and Related Disorders
  • CAR-T cell therapy research
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Diverse Scientific and Economic Studies
  • Diverse Scientific and Economic Studies
  • Human auditory perception and evaluation
  • Human auditory perception and evaluation
  • Single-cell and spatial transcriptomics
  • Single-cell and spatial transcriptomics
  • Educational Robotics and Engineering
  • Educational Robotics and Engineering
  • Pluripotent Stem Cells Research
  • Pluripotent Stem Cells Research
  • Immune Response and Inflammation
  • Immune Response and Inflammation
  • Cytokine Signaling Pathways and Interactions
  • Multiple Myeloma Research and Treatments
  • Multiple Myeloma Research and Treatments
  • Cytokine Signaling Pathways and Interactions

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: